CN1120314A - 治疗骨质疏松症的方法和组合物 - Google Patents

治疗骨质疏松症的方法和组合物 Download PDF

Info

Publication number: CN1120314A
Authority: CN; China
Prior art keywords: estrogen; potassium salt; amount; patient; osteoporosis
Prior art date: 1993-04-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN94191682A

Other languages

English (en)

Chinese (zh)

Inventor

R·柯蒂斯·莫里斯Jr

安东尼·塞巴斯蒂安

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of California

Original Assignee

University of California

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-04-02

Filing date

1994-03-29

Publication date

1996-04-10

1994-03-29 Application filed by University of California filed Critical University of California

1996-04-10 Publication of CN1120314A publication Critical patent/CN1120314A/zh

Status Pending legal-status Critical Current

Links

208000001132 Osteoporosis Diseases 0.000 title claims abstract description 37
238000000034 method Methods 0.000 title claims description 27
239000000203 mixture Substances 0.000 title description 24
229940011871 estrogen Drugs 0.000 claims abstract description 57
239000000262 estrogen Substances 0.000 claims abstract description 57
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims abstract description 44
210000002700 urine Anatomy 0.000 claims abstract description 18
235000015497 potassium bicarbonate Nutrition 0.000 claims abstract description 12
229910000028 potassium bicarbonate Inorganic materials 0.000 claims abstract description 12
239000011736 potassium bicarbonate Substances 0.000 claims abstract description 12
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims abstract description 12
239000012530 fluid Substances 0.000 claims abstract description 6
238000001727 in vivo Methods 0.000 claims abstract description 4
239000004480 active ingredient Substances 0.000 claims abstract description 3
239000003814 drug Substances 0.000 claims description 39
229940079593 drug Drugs 0.000 claims description 34
230000001076 estrogenic effect Effects 0.000 claims description 25
230000029142 excretion Effects 0.000 claims description 17
229940088597 hormone Drugs 0.000 claims description 17
239000005556 hormone Substances 0.000 claims description 17
229940035811 conjugated estrogen Drugs 0.000 claims description 15
239000002552 dosage form Substances 0.000 claims description 15
QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 13
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 12
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 10
229910052791 calcium Inorganic materials 0.000 claims description 10
239000011575 calcium Substances 0.000 claims description 10
102000008186 Collagen Human genes 0.000 claims description 8
108010035532 Collagen Proteins 0.000 claims description 8
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 8
229920001436 collagen Polymers 0.000 claims description 8
239000011574 phosphorus Substances 0.000 claims description 8
229910052698 phosphorus Inorganic materials 0.000 claims description 8
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 7
238000004132 cross linking Methods 0.000 claims description 7
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 7
150000002148 esters Chemical class 0.000 claims description 7
229960002591 hydroxyproline Drugs 0.000 claims description 7
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 7
230000003203 everyday effect Effects 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
238000002560 therapeutic procedure Methods 0.000 claims description 6
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
229910052739 hydrogen Inorganic materials 0.000 claims description 3
239000001257 hydrogen Substances 0.000 claims description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
229910052760 oxygen Inorganic materials 0.000 claims description 3
239000001301 oxygen Substances 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
150000001875 compounds Chemical class 0.000 claims 2
230000002354 daily effect Effects 0.000 claims 2
235000012976 tarts Nutrition 0.000 claims 2
230000004927 fusion Effects 0.000 claims 1
159000000001 potassium salts Chemical class 0.000 abstract description 3
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 abstract description 2
-1 hydroxyl ions Chemical class 0.000 abstract description 2
150000001735 carboxylic acids Chemical class 0.000 abstract 1
230000001009 osteoporotic effect Effects 0.000 description 16
230000000694 effects Effects 0.000 description 12
239000000583 progesterone congener Substances 0.000 description 8
239000003826 tablet Substances 0.000 description 8
230000011164 ossification Effects 0.000 description 7
235000013305 food Nutrition 0.000 description 6
231100000206 health hazard Toxicity 0.000 description 5
239000006187 pill Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
206010014759 Endometrial neoplasm Diseases 0.000 description 4
230000033228 biological regulation Effects 0.000 description 4
210000000988 bone and bone Anatomy 0.000 description 4
239000002775 capsule Substances 0.000 description 4
201000003914 endometrial carcinoma Diseases 0.000 description 4
238000011160 research Methods 0.000 description 4
239000007787 solid Substances 0.000 description 4
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 3
208000006386 Bone Resorption Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000004067 Osteocalcin Human genes 0.000 description 3
108090000573 Osteocalcin Proteins 0.000 description 3
230000024279 bone resorption Effects 0.000 description 3
210000003608 fece Anatomy 0.000 description 3
239000008187 granular material Substances 0.000 description 3
230000006872 improvement Effects 0.000 description 3
238000002372 labelling Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000000737 periodic effect Effects 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000002265 prevention Effects 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
230000009467 reduction Effects 0.000 description 3
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
150000000307 17β-estradiols Chemical class 0.000 description 2
ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
241000287433 Turdus Species 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000002079 cooperative effect Effects 0.000 description 2
239000003431 cross linking reagent Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
229960003399 estrone Drugs 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
229960003975 potassium Drugs 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
229960001424 quinestrol Drugs 0.000 description 2
PWZUUYSISTUNDW-VAFBSOEGSA-N quinestrol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 PWZUUYSISTUNDW-VAFBSOEGSA-N 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000005728 strengthening Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
RYWZPRVUQHMJFF-BZSNNMDCSA-N (13s,14s,17s)-13-methyl-11,12,14,15,16,17-hexahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2C(CC[C@]3([C@H]4CC[C@@H]3O)C)=C4C=CC2=C1 RYWZPRVUQHMJFF-BZSNNMDCSA-N 0.000 description 1
PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
AOPDRZXCEAKHHW-UHFFFAOYSA-N 1-pentoxypentane Chemical compound CCCCCOCCCCC AOPDRZXCEAKHHW-UHFFFAOYSA-N 0.000 description 1
RYWZPRVUQHMJFF-KSZLIROESA-N 17alpha-Dihydroequilenin Chemical compound OC1=CC=C2C(CC[C@]3([C@H]4CC[C@H]3O)C)=C4C=CC2=C1 RYWZPRVUQHMJFF-KSZLIROESA-N 0.000 description 1
RYWZPRVUQHMJFF-UHFFFAOYSA-N 17alpha-Dihydroequilenin Natural products OC1=CC=C2C(CCC3(C4CCC3O)C)=C4C=CC2=C1 RYWZPRVUQHMJFF-UHFFFAOYSA-N 0.000 description 1
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
150000000304 17α-estradiols Chemical class 0.000 description 1
NLLMJANWPUQQTA-UBDQQSCGSA-N 7,8-didehydro-17beta-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4C3=CCC2=C1 NLLMJANWPUQQTA-UBDQQSCGSA-N 0.000 description 1
206010059245 Angiopathy Diseases 0.000 description 1
UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
208000018083 Bone metabolism disease Diseases 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
244000131522 Citrus pyriformis Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010030247 Oestrogen deficiency Diseases 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
244000203593 Piper nigrum Species 0.000 description 1
HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
LCYXYLLJXMAEMT-SAXRGWBVSA-N Pyridinoline Chemical compound OC(=O)[C@@H](N)CCC1=C[N+](C[C@H](O)CC[C@H](N)C([O-])=O)=CC(O)=C1C[C@H](N)C(O)=O LCYXYLLJXMAEMT-SAXRGWBVSA-N 0.000 description 1
VPMWDFRZSIMDKW-YJYMSZOUSA-N Salmefamol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 VPMWDFRZSIMDKW-YJYMSZOUSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
208000001435 Thromboembolism Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
125000003158 alcohol group Chemical group 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000000680 avirulence Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
239000003150 biochemical marker Substances 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000002805 bone matrix Anatomy 0.000 description 1
230000004097 bone metabolism Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229950004783 cipionate Drugs 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000011443 conventional therapy Methods 0.000 description 1
PDRGHUMCVRDZLQ-UHFFFAOYSA-N d-equilenin Natural products OC1=CC=C2C(CCC3(C4CCC3=O)C)=C4C=CC2=C1 PDRGHUMCVRDZLQ-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
208000016018 endometrial polyp Diseases 0.000 description 1
PDRGHUMCVRDZLQ-WMZOPIPTSA-N equilenin Chemical compound OC1=CC=C2C(CC[C@]3([C@H]4CCC3=O)C)=C4C=CC2=C1 PDRGHUMCVRDZLQ-WMZOPIPTSA-N 0.000 description 1
WKRLQDKEXYKHJB-HFTRVMKXSA-N equilin Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 WKRLQDKEXYKHJB-HFTRVMKXSA-N 0.000 description 1
NLLMJANWPUQQTA-SPUZQDLCSA-N estra-1,3,5(10),7-tetraene-3,17alpha-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4C3=CCC2=C1 NLLMJANWPUQQTA-SPUZQDLCSA-N 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229950002007 estradiol benzoate Drugs 0.000 description 1
229960001348 estriol Drugs 0.000 description 1
PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
VUCAHVBMSFIGAI-ZFINNJDLSA-M estrone sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 VUCAHVBMSFIGAI-ZFINNJDLSA-M 0.000 description 1
230000012173 estrus Effects 0.000 description 1
229960002568 ethinylestradiol Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
208000020694 gallbladder disease Diseases 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
238000001794 hormone therapy Methods 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000009245 menopause Effects 0.000 description 1
230000002175 menstrual effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
239000001508 potassium citrate Substances 0.000 description 1
229960002635 potassium citrate Drugs 0.000 description 1
QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
235000011082 potassium citrates Nutrition 0.000 description 1
239000004224 potassium gluconate Substances 0.000 description 1
229960003189 potassium gluconate Drugs 0.000 description 1
235000013926 potassium gluconate Nutrition 0.000 description 1
229940063238 premarin Drugs 0.000 description 1
230000008569 process Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229950001879 salmefamol Drugs 0.000 description 1
239000011833 salt mixture Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229960004249 sodium acetate Drugs 0.000 description 1
159000000000 sodium salts Chemical group 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229940117013 triethanolamine oleate Drugs 0.000 description 1
229960004418 trolamine Drugs 0.000 description 1
229940116269 uric acid Drugs 0.000 description 1
206010046811 uterine polyp Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physical Education & Sports Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Inorganic Chemistry (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CN94191682A 1993-04-02 1994-03-29 治疗骨质疏松症的方法和组合物 Pending CN1120314A (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US4234993A	1993-04-02	1993-04-02
US08/042,349		1993-04-02

Publications (1)

Publication Number	Publication Date
CN1120314A true CN1120314A (zh)	1996-04-10

Family

ID=21921399

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN94191682A Pending CN1120314A (zh)	1993-04-02	1994-03-29	治疗骨质疏松症的方法和组合物

Country Status (8)

Country	Link
EP (1)	EP0692965A4 (ja)
JP (1)	JPH08508502A (ja)
KR (1)	KR960701642A (ja)
CN (1)	CN1120314A (ja)
AU (1)	AU692155B2 (ja)
BR (1)	BR9406101A (ja)
CA (1)	CA2159354A1 (ja)
WO (1)	WO1994022457A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN106132912A (zh) *	2014-04-02	2016-11-16	国际壳牌研究有限公司	用于分离单乙二醇和1,2‑丁二醇的方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2441252A1 (en) *	2001-03-16	2002-10-10	Wyeth	Estrogen replacement therapy
CA2534577A1 (en) *	2003-08-06	2005-02-24	Rhodia, Inc.	Method for promoting bone growth

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3608077A (en) *	1969-11-13	1971-09-21	Syntex Corp	Stabilization of metal steroid alcohol sulfates
US4078060A (en) *	1976-05-10	1978-03-07	Richardson-Merrell Inc.	Method of inducing an estrogenic response
US4261985A (en) *	1978-11-22	1981-04-14	Ciba-Geigy Corporation	Novel diuretics
US4617298A (en) *	1985-10-22	1986-10-14	University Of Florida	Method and compositions for weight control
US4814177A (en) *	1986-03-18	1989-03-21	Board Of Regents, University Of Texas System	Ultradense and more soluble and bioavailable preparations of calcium citrate
US5171583A (en) *	1988-10-21	1992-12-15	The Regents Of The University Of California	Treatment of osteoporosis using potassium bicarbonate

1994
- 1994-03-29 BR BR9406101A patent/BR9406101A/pt not_active Application Discontinuation
- 1994-03-29 KR KR1019950704281A patent/KR960701642A/ko not_active Application Discontinuation
- 1994-03-29 WO PCT/US1994/003402 patent/WO1994022457A1/en not_active Application Discontinuation
- 1994-03-29 JP JP6522294A patent/JPH08508502A/ja active Pending
- 1994-03-29 AU AU66219/94A patent/AU692155B2/en not_active Ceased
- 1994-03-29 EP EP94913970A patent/EP0692965A4/en not_active Withdrawn
- 1994-03-29 CN CN94191682A patent/CN1120314A/zh active Pending
- 1994-03-29 CA CA002159354A patent/CA2159354A1/en not_active Abandoned

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN106132912A (zh) *	2014-04-02	2016-11-16	国际壳牌研究有限公司	用于分离单乙二醇和1,2‑丁二醇的方法

Also Published As

Publication number	Publication date
EP0692965A1 (en)	1996-01-24
KR960701642A (ko)	1996-03-28
EP0692965A4 (en)	1998-08-12
CA2159354A1 (en)	1994-10-13
AU692155B2 (en)	1998-06-04
WO1994022457A1 (en)	1994-10-13
AU6621994A (en)	1994-10-24
BR9406101A (pt)	1995-12-19
JPH08508502A (ja)	1996-09-10

Legal Events

Date	Code	Title
1996-04-10	C06	Publication
1996-04-10	PB01	Publication
1996-07-10	C10	Entry into substantive examination
1996-07-10	SE01	Entry into force of request for substantive examination
2003-01-08	C02	Deemed withdrawal of patent application after publication (patent law 2001)
2003-01-08	WD01	Invention patent application deemed withdrawn after publication

Publication	Publication Date	Title
CN1137691C (zh)	2004-02-11	基于天然***的多相避孕制剂
AU680239B2 (en)	1997-07-24	Hormone replacement therapy
US5382573A (en)	1995-01-17	Hormone preparation and method
US4826831A (en)	1989-05-02	Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
JP3208482B2 (ja)	2001-09-10	避妊製剤
CN1076969C (zh)	2002-01-02	含有至少一种孕激素和至少一种***的替代治疗用制剂
CN1142185A (zh)	1997-02-05	避孕组合物
JPH04290830A (ja)	1992-10-15	避妊薬処方物
ZA200106006B (en)	2002-10-21	Triphasic oral contraceptive.
CN1186024C (zh)	2005-01-26	单阶段避孕方法和含有*和*组合物的避孕药盒
KR100782638B1 (ko)	2007-12-06	에스트로겐 화합물 및 프로게스테론 화합물로 이루어진호르몬 조성물
Bainton	1986	Interaction between antibiotic therapy and contraceptive medication
JP2942560B2 (ja)	1999-08-30	エストロゲン欠乏症治療用組成物
CN1120314A (zh)	1996-04-10	治疗骨质疏松症的方法和组合物
RU2215540C2 (ru)	2003-11-10	Схемы приема гестаген-антигестагена
CN1382054A (zh)	2002-11-27	新避孕药及其制法
CN1047974A (zh)	1990-12-26	实现避孕的组合物与方法
AU729898B2 (en)	2001-02-15	Transdermal therapeutic system having an active compound combination comprising oestriol
CN1111512A (zh)	1995-11-15	抗早孕药物组合物
JPH11501649A (ja)	1999-02-09	閉経周辺期及び閉経前期にある女性に対する徐放性避妊薬としての及びホルモン補充療法に使用する１月用注射薬
JPH0692856A (ja)	1994-04-05	エストリオールの高血中濃度が得られる軟膏剤
MXPA99001793A (en)	2000-02-02	Transdermal therapeutical approach involving a combination of active substances containing oestriol
ZA200106689B (en)	2002-11-14	Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding.
CN1178465A (zh)	1998-04-08	一月针剂作为长效避孕药和用于绝经期间和绝经期前妇女的激素替代治疗

CN1120314A - 治疗骨质疏松症的方法和组合物 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=21921399

Family Applications (1)

Country Status (8)

Cited By (1)

Families Citing this family (2)

Family Cites Families (6)

Cited By (1)

Also Published As

Similar Documents

Legal Events